How J&J's Coronavirus Vaccine Fiasco Could Benefit Novavax And Others

How J&J's Coronavirus Vaccine Fiasco Could Benefit Novavax And Others
ALLISON GATLIN
·4 min read

The extended pause for Johnson & Johnson's coronavirus vaccine in the U.S. could bolster vaccine stocks Pfizer, Moderna and Novavax, experts say. And the question of herd immunity looms.